

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

ALPINE GROUP, INC.

2. Address:

660 PENNSYLVANIA AVE SE #201, WASHINGTON, DC 20003

3. Principal place of business (if different from line 2):

4. Contact Name: ALICIA FITZPATRICK

Telephone: 2025482316

E-mail (optional): afitzpatrick@alpinegroup.com

Senate ID #: 1171-87

House ID #: 31749005

7. Client Name: ☐ Self

COUNCIL ON RADIONUCLIDES & RADIOPHARMACEUTICALS

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 240,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: ALPINE GROUP, INC. Client Name: COUNCIL ON RADIONUCLIDES &
RADIOPHARMACEUTICALS
LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: ENG (one per page)

16. Specific lobbying issues:

S. 858, Nuclear Fees Reauthorization Act of 2005 S. 864, Nuclear Safety and Security Act of 2005 S. 2145, Chemical Facility Anti-terrorism Act H.R. 5695, Chemical Facility Anti-terrorism Act of 2006 Nuclear Safety Issues Energy Issues H.R. 2689, Dirty Bomb Prevention Act H.R. 2237, Chemical Security Act of 2005 H.R. 1562, Chemical Facility Security Act of 2005 S. 1150, Dirty Bomb Prevention Act

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BARNETT, CHARLES

Covered Official Position (if applicable): N/A

Name: JOHNSON, COURTNEY

Covered Official Position (if applicable): N/A

Name: MASSIE, JAMES D.

Covered Official Position (if applicable): N/A

Name: WHITE, RICHARD C.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ALPINE GROUP, INC. Client Name: COUNCIL ON RADIONUCLIDES &
RADIOPHARMACEUTICALS
LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Implementation of Food and Drug Administration Modernization and Accountability Act of 1997, provisions dealing with the review and approval of radiopharmaceuticals. Re-establishment of medical imaging advisory committee at FDA.

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JOHNSON, COURTNEY

Covered Official Position (if applicable): N/A

Name: MASSIE, JAMES D.

Covered Official Position (if applicable): N/A

Name: WHITE, RICHARD C.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ALPINE GROUP, INC. Client Name: COUNCIL ON RADIONUCLIDES &
RADIOPHARMACEUTICALS
LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Implementation of Medicare Modernization Act, provisions related to reimbursement for radiopharmaceuticals. CMS proposed 2007 regulations on hospital outpatient prospective payment system

17. House(s) of Congress and Federal agencies contacted:
Centers For Medicare and Medicaid Services (CMS)
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HAWKINS, JAMES

Covered Official Position (if applicable): N/A

Name: JOHNSON, COURTNEY

Covered Official Position (if applicable): N/A

Name: MASSIE, JAMES D.

Covered Official Position (if applicable): N/A

Name: WHITE, RICHARD C.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ALPINE GROUP, INC. Client Name: COUNCIL ON RADIONUCLIDES &
RADIOPHARMACEUTICALS
LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRA (one per page)

16. Specific lobbying issues:

the Terrorism Prevention in Hazardous Materials Transportation Temporary Act of 2005, as passed by the Council of the District of Columbia, from taking effect. H.R. 3, Transportation Equity Act: A Legacy for Users, provisions dealing with the transportation of radiopharmaceuticals. S. 1052, Transportation Improvement Security Act Homeland security Provisions dealing with shipments of radiopharmaceuticals and radionuclides. H.R.1414, Extremely Hazardous Materials Transportation Security Act of 2005 H.R. 2057, To prevent the Terrorism Prevention in Hazardous Materials Transportation Emergency Act of 2005 and

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

Transportation, Dept of (DOT)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JOHNSON, COURTNEY

Covered Official Position (if applicable): N/A

Name: MASSIE, JAMES D.

Covered Official Position (if applicable): N/A

Name: WHITE, RICHARD C.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 06, 2007

Printed Name and Title: ALICIA FITZPATRICK, ASSOCIATE -